< Back to situations

[ORGANIZATION]

Medicines and Healthcare products Regulatory Agency (MHRA)

Featured in 7 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [US] [BR] [GB]

GLP-1 drugs: clinical trends, safety, and market shifts

259 clusters · 928 sources · last updated

Latest: Medical experts warn of weight regain risks for GLP-1 users

Since mid-2026, the expansion of GLP-1 agents for obesity has been accompanied by intensified safety monitoring and evolving clinical data. Research suggests secondary benefits, including a 21% lower risk of fragility fr

[QUIET] [HEALTH] [GB] [US]

Aficamten development for hypertrophic cardiomyopathy

3 clusters · 4 sources · last updated

Latest: New therapies show promise for treating hypertrophic cardiomyopathy

The cardiac myosin inhibitor aficamten (brand name Myqorzo) is expanding its clinical application and regulatory reach for hypertrophic cardiomyopathy (HCM). In England, the Medicines and Healthcare products Regulatory

Also covered in